SSTR2 and neoplasm: Compared to Fuchs et al., our findings showed consistently higher SSTR2 positivity across all tumour lineages: thyrotrophs (100% vs. 18%), somatotrophs (95.3% vs. 64%), gonadotrophs (82.8% vs. 15%), corticotrophs (75.9% vs. 28%), lactotrophs (55.6% vs. 22%) and null cell adenomas (47.2% vs. 22%).9